PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 116 products of "PD-1/PD-L1"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
D5B
D5B is an effective and selective PD-L1 inhibitor that has been modified with DBCO. It degrades PD-L1 in 4T1 and B16-F10 tumor cells with EC50 values of 5.4 μM and 6.2 μM, respectively. D5B can block the PD-L1/PD-1 interaction and exhibits antitumor activity.Formula:C58H66N2O12Color and Shape:SolidMolecular weight:983.15Lon-TK
Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.Formula:C24H28Cl2N2O3S2Color and Shape:SolidMolecular weight:527.53PD-1/PD-L1-IN-32
PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM.Purity:98%Color and Shape:Odour SolidPD-1/PD-L1-IN-31
PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral bloodFormula:C24H24ClFN2O3Purity:98%Color and Shape:SolidMolecular weight:442.91(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstratingFormula:C72H99F3N20O23Purity:98%Color and Shape:SolidMolecular weight:1669.67LP23
LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/JurkatFormula:C27H27N3O5SPurity:98%Color and Shape:SolidMolecular weight:505.59IMMH 010 maleate
CAS:IMMH 010 maleate (YPD-30 maleate) is a programmed cell death ligand 1 inhibitor used in the study of neurological disorders and advanced malignant solid tumors.Formula:C36H36BrClN2O9Color and Shape:SoildMolecular weight:756.04ARB-272572 hydrochloride
CAS:ARB-272572 hydrochloride is a PD-L1 inhibitor that inhibits PD-1/PD-L1 cell signaling by inducing PD-L1 protein homology interactions.Formula:C32H36N6O4·xClHPurity:99.38%Color and Shape:SoildMolecular weight:568.68(Free base）PD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.Formula:C22H22N2O3Color and Shape:SolidMolecular weight:362.42PD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purity:99.92%Color and Shape:SolidMolecular weight:348.44Ref: TM-T9651
1mg57.00€2mg85.00€5mg127.00€10mg178.00€25mg298.00€50mg405.00€100mg535.00€500mg1,063.00€1mL*10mM (DMSO)140.00€TPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formula:C109H151F3N34O34S2Color and Shape:SolidMolecular weight:2602.69PD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Color and Shape:Odour SolidHuman PD-L1 inhibitor I
CAS:Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formula:C110H152N26O32Color and Shape:SolidMolecular weight:2350.576BMSpep-57
CAS:BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.Formula:C89H126N24O19SColor and Shape:SolidMolecular weight:1868.2PD-L1 inhibitory peptide
CAS:PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.Formula:C96H135N21O23SColor and Shape:SolidMolecular weight:1983.29Human PD-L1 inhibitor IV
CAS:PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Formula:C80H113N25O27Color and Shape:SolidMolecular weight:1856.932Human PD-L1 inhibitor III
CAS:Human PD-L1 inhibitor III is a human PD-L1 inhibitor.Formula:C97H155N29O29SColor and Shape:SolidMolecular weight:2223.54PD-L1-IN-5
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.
PD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Formula:C23H20ClFN2O3Molecular weight:426.11465PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.OPBP-1
OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.Formula:C64H92N20O19SMolecular weight:1476.65683Camrelizumab
CAS:Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up
Purity:95% - 98.6%Color and Shape:LiquidMolecular weight:143.7 kDaPacmilimab
CAS:Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.Purity:98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Color and Shape:LiquidProlgolimab
CAS:Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.Purity:>95%Color and Shape:LiquidMolecular weight:146.28 kDaHuman membrane-bound PD-L1 polypeptide
CAS:Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].Formula:C85H140N26O36SPurity:98%Color and Shape:SolidMolecular weight:2134.24H-20
CAS:H-20 is a PD-1 agonist that reduces the required dosage of morphine for analgesia. It can be used in studies related to chronic pain.Formula:C44H64N10O15Color and Shape:SolidMolecular weight:973.037N-deacetylated BMS-202
CAS:N-deacetylated BMS-202 is an inhibitor of PD-1/PD-L1 interaction with potential anticancer activity for cancer research.Formula:C23H27N3O2Purity:98.13% - 98.13%Color and Shape:SolidMolecular weight:377.48BMS-1166
CAS:BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.Formula:C36H33ClN2O7Purity:99.22%Color and Shape:SolidMolecular weight:641.11Ref: TM-T5697
1mg71.00€5mg146.00€10mg213.00€25mg406.00€50mg602.00€100mg893.00€200mg1,198.00€1mL*10mM (DMSO)197.00€BMS-8
CAS:BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.Formula:C27H28BrNO3Purity:98.88%Color and Shape:SolidMolecular weight:494.42Ref: TM-T26859
1mg37.00€5mg79.00€10mg124.00€25mg222.00€50mg340.00€100mg505.00€200mg705.00€1mL*10mM (DMSO)86.00€Pembrolizumab
CAS:Pembrolizumab (MK-3475) is a humanized monoclonal antibody.Cost-effective and quality-assured.Purity:95% - 99.70%Color and Shape:LiquidMolecular weight:149 kDaBMS-1001
CAS:BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).Formula:C35H34N2O7Purity:98.43%Color and Shape:SolidMolecular weight:594.7Ref: TM-T8470
1mg58.00€5mg124.00€10mg177.00€25mg299.00€50mg424.00€100mg587.00€200mg792.00€1mL*10mM (DMSO)172.00€Nivolumab
CAS:Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.Purity:98% - 98%Color and Shape:LiquidMolecular weight:143.62 kDaAvelumab
CAS:Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.Purity:95% - 97.17% (SDS-PAGE)Color and Shape:LiquidMolecular weight:143.8 kDaBMS-1166-n-piperidine-co-n-piperazine dihydrochloride
CAS:BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (Formula:C41H45Cl3N4O5Purity:98.94%Color and Shape:SoildMolecular weight:780.18Envafolimab
CAS:Envafolimab (ASC 22) is a humanized antibody targeting PD-L1, with anticancer activity, blocking the PD-L1 and PD-1 interaction.Purity:95%Color and Shape:LiquidMolecular weight:80 kDaARB-272572
CAS:ARB-272572 is a PD-L1 signaling inhibitor that produces immunostimulatory activity in human primary cells.Formula:C32H36N6O4Purity:97.36% - 98.07%Color and Shape:SolidMolecular weight:568.67Ref: TM-T39914
1mg123.00€5mg295.00€10mg425.00€25mg712.00€50mg1,035.00€100mg1,485.00€200mg1,998.00€1mL*10mM (DMSO)353.00€Socazolimab
CAS:Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1 with antitumor activity, used in studies of recurrent or metastatic cervical cancer.Purity:95%Color and Shape:LiquidMolecular weight:143.06 kDaLesabelimab
CAS:Lesabelimab (LDP) is an anti-CD274 monoclonal antibody of the immunoglobulin G1-kappa subclass.Color and Shape:LiquidAcasunlimab
CAS:Acasunlimab (GEN1046) is a bsAb that targets PD-L1 and 4-1BB, boosting T/NK cells and blocking PD-1/PD-L1 in cancer research.Color and Shape:LiquidToripalimab
CAS:Toripalimab is a humanized anti-PD-1 monoclonal antibody used as an immune checkpoint inhibitor in research for advanced malignancies like nasopharyngeal carcinoma.Purity:95% - 95.2% (SDS-PAGE); 96.8% (SEC-HPLC)Color and Shape:LiquidAnti-Mouse/Human phosphorylated PD-1/CD279 Antibody
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is an IgG2a, κ antibody inhibitor derived from mice, targeting phosphorylated PD-1/CD279 in both mice and humans.Color and Shape:Odour LiquidAnti-Mouse PD-1 Antibody (S-5001)
Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.Color and Shape:Odour LiquidTuvonralimab
CAS:Tuvonralimab, a combo of anti-PD-1/IgG4 and anti-CTLA-4/IgG1 antibodies, blocks dual immune checkpoints.Purity:95% - 95%Color and Shape:LiquidReozalimab
CAS:Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, antitumour and enhances T-cell activation in vitro.Purity:95% - 98.1% (SDS-PAGE); 96.2% (SEC-HPLC)Color and Shape:LiquidMolecular weight:144.16 kDaSugemalimab
CAS:Sugemalimab: human anti-PD-L1 IgG4 mAb with anticancer properties for non-small cell lung cancer.
Color and Shape:LiquidGilvetmab
CAS:Gilvetmab is a caninized anti-PD-1 antibody approved for veterinary use, researched for stage I-III mast cell tumors and stage II-III melanoma in dogs.Purity:95% - 97.9% (SDS-PAGE); 97.4% (SEC-HPLC)Color and Shape:LiquidMolecular weight:147.95 kDaRosnilimab
CAS:Rosnilimab is a PD-1 agonist that inhibits T cell proliferation and depletes T cells, enabling research into inflammatory diseases.Purity:95% - 98.9% (SDS-PAGE); 98.7% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146.57 kDaPD-1-IN-22
CAS:PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).Formula:C25H25N5O4Purity:99.51%Color and Shape:SolidMolecular weight:459.5Ref: TM-T12379
1mg109.00€2mg163.00€5mg243.00€10mg355.00€25mg532.00€50mg750.00€100mg1,009.00€500mg2,035.00€1mL*10mM (DMSO)284.00€PD-1/PD-L1-IN-NP19
CAS:PD-1/PD-L1-IN-NP19: a PD-1/PD-L1 inhibitor with 12.5 nM IC50, may boost antitumor immunity.Formula:C33H31ClN2O4Purity:96.70%Color and Shape:SolidMolecular weight:555.06PD-1/PD-L1-IN-20
CAS:PD-1/PD-L1-IN-20 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interaction.Formula:C30H26BrClN2O3Color and Shape:SolidMolecular weight:577.9
